US Stock Insider Trading | Regeneron Pharmaceuticals Discloses 12 Insider Transactions on February 23

2026-02-24 18:00:27

Abstract generation in progress

On February 23, 2026, Regeneron Pharmaceuticals (REGN) disclosed 12 insider trading transactions. Director Zoghbi Huda Y purchased 1,638 shares on February 19, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	208	779.55	162,100
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	298	782.10	233,100
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	50	775.50	38,800
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	53	778.47	41,300
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	331	780.45	258,300
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	209	781.28	163,300
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Buy	1,638	376.69	617,000
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	49	774.68	38,000
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	160	784.45	125,500
2026-02-23	Director	Zoghbi Huda Y	2026-02-19	Sell	220	783.29	172,300

[Company Profile]

Regeneron Pharmaceuticals was incorporated in New York State in 1988. The company is a fully integrated biotechnology firm that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its core business strategy is built on a strong foundation of research and proprietary technology, advancing a diversified portfolio of products and candidates across multiple therapeutic areas.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.